NCT07388992 Investigating Specific Gait Patterns in Individuals Living With Multiple Sclerosis
| NCT ID | NCT07388992 |
| Status | Recruiting |
| Phase | — |
| Sponsor | SYSNAV |
| Condition | Multiple Sclerosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 30 participants |
| Start Date | 2026-03-16 |
| Primary Completion | 2026-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 30 participants in total. It began in 2026-03-16 with a primary completion date of 2026-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study aims to investigate specific ambulation patterns characteristic of the quality of gait in people with MS (pwMS)
Eligibility Criteria
Inclusion Criteria: For people living with multiple sclerosis (pwMS): 1. Age at inclusion between =18 and =65 years old 2. Signed informed consent and ability to comply with study and follow-up. 3. Confirmed MS diagnosis according to McDonald criteria (2017) 4. Expanded Disability Status Scale EDSS = 6 5. Stable treatment for 2 months before inclusion (for both disease modifying and symptomatic therapies) 6. Ability and willingness to participate in and comply with all study procedures defined in the protocol 7. Subject will be eligible for enrollment in this study only if either affiliated to, or a beneficiary of a social security category For Healthy volunteers : 1. Age at inclusion between =18 and =65 years old 2. Signed informed consent and ability to comply with study and follow-up. 3. Ability and willingness to participate in and comply with all study procedures defined in the protocol 4. Subject will be eligible for enrollment in this study only if either affiliated to, or a beneficiary of a social security category Exclusion Criteria: For pwMS: 1. Participants with a relapse within the past 3 months before the inclusion 2. Participants with significant cognitive disorders, limiting the understanding of the exercises to be performed or presence of apparent communication difficulties hindering the correct collection of data, as assessed by the investigator 3. Past or present pathology other than MS or surgery or trauma impacting gait, ambulatory function or upper limb function, as assessed by the investigator 4. Vulnerable adults: individuals subject to a legal protection measure (guardianship, limited guardianship, or judicial protection) or unable to express their consent. For healthy volunteers (HV): 1. Participants with significant cognitive disorders, limiting the understanding of the exercises to be performed or presence of apparent communication difficulties hindering the correct collection of data, as assessed by the investigator 2. Past or present pathology or surgery or trauma impacting gait, ambulatory function or upper limb function, as assessed by the investigator 3. Vulnerable adults: individuals subject to a legal protection measure (guardianship, limited guardianship, or judicial protection) or unable to express their consent.
Contact & Investigator
Patrick Vermersch
PRINCIPAL INVESTIGATOR
CHU Lille
Frequently Asked Questions
Who can join the NCT07388992 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Multiple Sclerosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07388992 currently recruiting?
Yes, NCT07388992 is actively recruiting participants. Contact the research team at ferial.toumi@sysnav.fr for enrollment information.
Where is the NCT07388992 trial being conducted?
This trial is being conducted at Lille, France.
Who is sponsoring the NCT07388992 clinical trial?
NCT07388992 is sponsored by SYSNAV. The principal investigator is Patrick Vermersch at CHU Lille. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.